8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Apr 15, 2026·SEC
Stereotaxis, Inc.(STXS)Earnings, Financials & Key Ratios
STXS•AMEX
$1.77
Price updated Jul 6, 2026
AboutStereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.Show more
- Revenue$32M+20.3%
- EBITDA-$21M+13.5%
- Net Income-$22M+10.0%
- EPS (Diluted)-0.25+16.7%
- Gross Margin52.73%-2.7%
- EBITDA Margin-63.49%+28.1%
- Operating Margin-68.3%+25.7%
- Net Margin-66.85%+25.2%
- ROE-143.55%+0.4%
STXS Price & Volume
Stereotaxis, Inc. (STXS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Challenge Robotic Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital runway
Key Thesis Takeaways
- Stereotaxis faces a critical juncture as it attempts to scale the Genesis robotic platform amidst significant revenue volatility and persistent operating deficits.
- While the company maintains a modest debt-to-equity ratio of 0.29, the ongoing reliance on external funding to cover SG&A expenses—which frequently exceed gross profit—creates a precarious liquidity profile.
- Investors should monitor whether the firm can achieve a self-sustaining financial state before its $13.4 million cash balance is further eroded by quarterly net losses that reached $5.9 million in 2026Q1.
Verdict Logic
the company's persistent cash burn, evidenced by a $3.5 million negative free cash flow in 2026Q1, suggests a high risk of future dilution given the limited $13.4 million cash buffer.
STXS Growth Metrics
Stereotaxis, Inc. (STXS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.5%
5 Years3.99%
3 Years4.78%
TTM13.4%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.51%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.97%
Return on Capital
10 Years-47.62%
5 Years-61.77%
3 Years-78.94%
Last Year-80.39%
STXS Recent Earnings
Stereotaxis, Inc. (STXS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.03+25.0%
$0.04
Rev
$6M-26.0%
$9M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.06+0.0%
$0.06
Rev
$9M-4.8%
$9M
Q4 2025
Nov 11, 2025Metric
Actual
Est
EPS
$0.03+50.0%
$0.06
Rev
$7M-19.2%
$9M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.05+28.6%
$0.07
Rev
$9M+4.3%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.03vs $0.04+25.0% | $6Mvs $9M-26.0% |
| Q2 2026 | Mar 9, 2026 | $0.06vs $0.06+0.0% | $9Mvs $9M-4.8% |
| Q4 2025 | Nov 11, 2025 | $0.03vs $0.06+50.0% | $7Mvs $9M-19.2% |
| Q3 2025 | Aug 7, 2025 | $0.05vs $0.07+28.6% | $9Mvs $8M+4.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Stereotaxis, Inc. (STXS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.77 | $172.99M | -7.08 | 20.28% | -66.85% | -143.55% | — | |
| $432.83 | $153.29B | 55.00 | 20.51% | 28.15% | 16.89% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $95.63 | $166.57B | 25.71 | 5.67% | 13.91% | 12.09% | — | |
| $44.60 | $66.29B | 22.99 | 19.87% | 17.23% | 14.67% | — | |
| $83.06 | $106.64B | 22.27 | 8.43% | 13.2% | 9.78% | — |
Compare STXS vs Peers
Stereotaxis, Inc. (STXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STXS SEC Filings & Documents
Stereotaxis, Inc. (STXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when STXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STXS Frequently Asked Questions
Stereotaxis, Inc. (STXS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Stereotaxis, Inc.'s revenue?
Stereotaxis, Inc. (STXS) reported $31.2M in revenue for fiscal year 2025. This represents a 164953% increase from $0.0M in 2002.
How fast is Stereotaxis, Inc. growing?
Stereotaxis, Inc. (STXS) grew revenue by 20.3% over the past year. This is strong growth.
Is STXS profitable?
Stereotaxis, Inc. (STXS) reported a net loss of $21.7M for fiscal year 2025.
Dividend & Returns
What is STXS's return on equity?
Stereotaxis, Inc. (STXS) has a return on equity (ROE) of -143.6%. Negative ROE indicates the company is unprofitable.
What is Stereotaxis, Inc.'s free cash flow?
Stereotaxis, Inc. (STXS) had negative free cash flow of $15.5M in fiscal year 2025, likely due to heavy capital investments.